XNAS
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | — | -0.14 | — | $0 | — | -1.33% | -14.96% | — |
| 2026-03-19 | Q4 2025 | — | -0.07 | — | $0 | — | -2.74% | -12.93% | -9.40% |
| 2025-11-07 | Q3 2025 |
| — |
| -0.07 |
| — |
| $0 |
| — |
| — |
| — |
| — |
| 2025-08-08 | Q2 2025 | — | -0.19 | — | $0 | — | +0.00% | +6.63% | -18.07% |
| 2025-03-28 | Q4 2024 | -8.00 | -0.94 | +88.25% | $0 | ✅ Beat | -6.01% | -8.27% | -12.78% |
| 2024-11-08 | Q3 2024 | -6.50 | -2.00 | +69.23% | $0 | ✅ Beat | +0.78% | -10.47% | -25.57% |
| 2024-08-13 | Q2 2024 | -44.00 | -17.50 | +60.23% | $0 | ✅ Beat | -7.17% | +5.94% | -29.40% |
| 2024-05-15 | Q1 2024 | -43.50 | -23.00 | +47.13% | $0 | ✅ Beat | +8.54% | -13.20% | -52.98% |
Showing last 8 quarters.